AUTHORS
Georgio Medawar, MD, Hagop Kantarjian, MD2, Hannah Goulart, MD3, Musa Yilmaz, MD4, Yesid Alvarado Valero, MD5, Alex Bataller, MD, PhD6, Jayastu Senapati, MBBS, MD, DM7, Tapan Kadia I, MD8, Gautam Borthakur, MD9, Ghayas C. Issa, MD10, Mahesh Swaminathan, MD11, Christina Simon12, Fadi G. Haddad, MD13, Guillermo Garcia-Manero, MD14, Rebecca Garris15, Nicholas Short, MD16, Elias Jabbour, MD17
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
Older adults with B-cell acute lymphoblastic leukemia (B-ALL) face a challenging prognosis, and the optimal strategy for de-escalating cytotoxic therapy remains undefined, particularly for patients (pts) ≥70 years or those unfit for intensive regimens. We report the updated results from a phase 2 trial evaluating a largely chemotherapy-free approach combining and inotuzumab ozogamicin (InO) and blinatumomab (Blina) in newly diagnosed older pts with Philadelphia chromosome-negative (Ph-neg) B-ALL, with a median follow-up of 3 years (yrs).
Methods
Eligible pts were ≥70 years or unfit pts aged 60–70 years with Ph-neg B-ALL and ECOG performance status ≤2. During cycle 1, pts received dexamethasone 20 mg IV days 1–4, vincristine 1 mg IV day 4, fractionated InO 0.6 mg/m² IV day 1 and 0.3 mg/m² IV day 8, followed by Blina IV days 15–28 (9 µg/day ×2 days, then 28 µg/day), then a 2-week rest period. Cycles 2–4 consisted of Blina 28 µg/day days 1–28, with InO 0.3 mg/m² days 1 and 8 during cycles 2–4 (maximum cumulative dose 2.7 mg/m²). Maintenance (cycles 5–8) comprised Blina 28 µg/day days 1–28; all cycles were given every 42 days. CD20-positive pts could receive rituximab 375 mg/m² IV days 2 and 9 during cycles 1–4. All pts received 12 intrathecal chemotherapy doses and ursodiol prophylaxis.
Results
Between April 2021 and April 2026, 20 pts were enrolled with a median age of 76 yrs (range 64–82); 19 pts (95%) were ≥70 years, and 55% were male. Ten pts (50%) had TP53 mutations (median VAF 43%, range 4–89%), 7 pts (38%) had adverse cytogenetics (KMT2Ar, complex karyotype, low hypodiploidy, or near triploidy), and 1 pt had Ph-like disease with CRLF2 rearrangement.
The overall response rate was 95% (19/20), with 18/19 (95%) achieving complete remission (CR). Among responding pts, 17/19 (89%) achieved measurable residual disease (MRD) negativity by flow cytometry (FC) at any point. Of 17 pts with NGS-based MRD assessment, 15 (88%) became NGS-negative at any time, 1 (6%) had results below the limit of detection (LOD), and 1 (6%) remained positive. On day 14 bone marrow evaluation prior to Blina initiation, 9/14 evaluable pts (64%) had achieved CR, of whom 3 (33%) were MRD-negative by FC. NGS MRD was tested in one of them and was below LOD. On post-induction or cycle 1 evaluation, 16/19 (84%) pts achieved CR with 14/16 (88%) tested FC MRD negative, and 3/7 (43%) tested NGS MRD negative.
At median follow-up of 34 months, the 3-yr event-free survival (EFS) and overall survival (OS) rates are 60% and 57%, respectively; no early deaths occurred. Two pts had disease relapse (11%) and died. Both had TP53 mutations with high-risk cytogenetics at baseline. Four patients died in CR1. Two pts had consolidative allogeneic stem cell transplantation (ASCT) in CR1; 1 remains in FC MRD-negative CR, 2 years post-ASCT; the other died on day +60 from ASCT-related complications. Three pts had CAR-T cell therapy, 1 for relapsed disease, who died in relapse, and 2 as consolidation for persistent NGS MRD+. Both remain are alive, in CR with NGS MRD below LOD at last follow-up. Five pts completed treatment per protocol; 1 voluntarily withdrew. At 3 yrs, competing risks analysis shows a cumulative incidence of relapse of 13% with non-relapse mortality of 24%. Causes for non-relapse mortality included myocardial infarction, pneumonia, non-infectious respiratory failure, hospice transition, and ASCT-related multiorgan failure.
The most frequent adverse events (AEs) were leukopenia (n=15), thrombocytopenia (n=11), neutropenia (n=10), AST elevation (n=7), ALT elevation (n=6), and altered mental status (n=4). The most common grade ≥3 AEs were leukopenia (n=8), neutropenia (n=8), thrombocytopenia (n=5), anemia (n=2), and altered mental status (n=3; Blina was held and reinitiated upon resolution). One pt developed grade 2 cytokine release syndrome managed without interruption of Blina. There were no cases of veno-occlusive disease or secondary myeloid malignancies.
Conclusion
This updated analysis continues to confirm that a near-complete chemotherapy-free regimen of Blina plus InO is well tolerated and leads to deep, durable remissions in older or unfit pts with Ph-neg B-ALL, with 3-yr EFS and OS rates of 60% and 57%, respectively. These compare favorably so far to mini-HyperCVD-Ino+/- Blina which we previously reported a 5-yr OS and RFS of 44% and 46%, respectively. Continued efforts to refine patient selection and supportive care strategies are needed.
DISCLOSURES
Georgio Medawar, MD: No relevant conflicts of interest to declare.